Burden of illness of follicular lymphoma and marginal zone lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Burden of illness of follicular lymphoma and marginal zone lymphoma

Published:2018-10-13 Issue:1 Volume:98 Page:175-183
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Monga Neerav,Nastoupil Loretta,Garside Jamie,Quigley Joan,Hudson Moira,O’Donovan Peter,Parisi Lori,Tapprich Christoph,Thieblemont Catherine

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s00277-018-3501-8/fulltext.html

Reference46 articles.

1. MacDonald D, Prica A, Assouline S, Christofides A, Lawrence T, Sehn LH (2016) Emerging therapies for the treatment of relapsed or refractory follicular lymphoma. Curr Oncol 23(6):407–417. https://doi.org/10.3747/co.23.3405

2. European Medicines Agency (2018) Public summary of opinion on orphan designation: venetoclax for the treatment of mantle cell lymphoma

3. Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trneny M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377(14):1331–1344. https://doi.org/10.1056/NEJMoa1614598

4. Jacobsen CA, Freedman AS (2012) Early stage follicular lymphoma, current management and controversies. Curr Opin Oncol 24(5):475–479. https://doi.org/10.1097/CCO.0b013e328356898b

5. Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, Federico M, Hoskin P, McNamara C, Caligaris-Cappio F, Stilgenbauer S, Marcus R, Trneny M, Dreger P, Montserrat E, Dreyling M (2013) ESMO guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol 24(3):561–576. https://doi.org/10.1093/annonc/mds517

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States;Journal of Medical Economics;2024-06-06

2. Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma;Blood Advances;2023-11-28

3. Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study;Haematologica;2023-09-28

4. Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal Zone Lymphoma in Ontario, Canada;Current Oncology;2023-04-30

5. Design of Novel Phosphatidylinositol 3-Kinase Inhibitors for Non-Hodgkin’s Lymphoma: Molecular Docking, Molecular Dynamics, and Density Functional Theory Studies on Gold Nanoparticles;Molecules;2023-03-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3